SHL Telemedicine Ltd

SHL Telemedicine has a fully diluted share count of 37,058,574 shares, with no difference between basic and diluted shares, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company reported a last actual EPS of $0.12 and revenue of $36.79 million, but no industry-specific preferred metrics or cohort medians are available for comparison. Without access to profitability metrics such as EBITDA or net margin, it is not possible to evaluate the company's returns relative to industry benchmarks. SHL Telemedicine's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk of overreliance on specific markets or customer segments. The company's growth trajectory is unclear, as no forward-looking revenue guidance or historical growth rates are provided in the input data. Analysts have not issued forward-looking estimates for the next fiscal year, limiting visibility into future performance. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. No dilution risk is currently identified, as the basic and diluted share counts are equal. No recent filings or transcripts are available in the input data to provide insight into management commentary, strategic shifts, or operational updates.